-
Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms Exp. Hematol. (IF 2.6) Pub Date : 2024-02-09 Taylor B. Collins, Angelo B.A. Laranjeira, Tim Kong, Mary C. Fulbright, Daniel A.C. Fisher, Christopher M. Sturgeon, Luis F.Z. Batista, Stephen T. Oh
[Display omitted]
-
Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome Exp. Hematol. (IF 2.6) Pub Date : 2024-02-09 Tatsuhiko Tanaka, Ko Kudo, Rika Kanezaki, Kentaro Yuzawa, Tsutomu Toki, Ryo Okuse, Akie Kobayashi, Tomohiko Sato, Takuya Kamio, Kiminori Terui, Etsuro Ito
Myeloid leukemia associated with Down syndrome (ML-DS) responds well to chemotherapy and has a favorable prognosis, but the clinical outcome of patients with refractory or relapsed ML-DS is dismal. We recently reported a case of relapsed ML-DS with an effective response to a DNA methyltransferase inhibitor, azacitidine (AZA). However, the efficacy of AZA for refractory or relapsed ML-DS remains uncertain
-
Zeb1 maintains long-term adult hematopoietic stem cell function and extramedullary hematopoiesis Exp. Hematol. (IF 2.6) Pub Date : 2024-02-08 Alhomidi Almotiri, Ali Abdelfattah, Elis Storch, Marc P. Stemmler, Simone Brabletz, Thomas Brabletz, Neil P. Rodrigues
Emerging evidence implicates the epithelial-mesenchymal transition transcription factor as a critical regulator of hematopoietic stem cell (HSC) differentiation. Whether regulates long-term maintenance of HSC function remains an open question. Using an inducible mouse model that deletes conditional alleles in the adult hematopoietic system, we found that mice engineered to be deficient in for 32 weeks
-
-
A novel kit mutant rat enables hematopoietic stem cell engraftment without irradiation Exp. Hematol. (IF 2.6) Pub Date : 2024-02-06 Ryuya Iida, Saeko Ishida, Jinxi Wang, Kosuke Hattori, Kazuto Yoshimi, Satoshi Yamazaki, Tomoji Mashimo
Hematopoietic stem cell (HSC) transplantation is extensively studied in mouse models, but their limited scale presents challenges for effective engraftment and comprehensive evaluations. Rats, due to their larger size and anatomical similarity to humans, offer a promising alternative. In this study, we establish a rat model with the mutation, mirroring mice often used in KIT signaling and HSC research
-
In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts Exp. Hematol. (IF 2.6) Pub Date : 2024-02-05 Joanna Randall, Kathryn Evans, Ben Watts, Hansen J. Kosasih, Christopher M. Smith, Eric J. Earley, Stephen W. Erickson, Emily L. Jocoy, Carol J. Bult, Beverly A. Teicher, Charles E. de Bock, Malcolm A. Smith, Richard B. Lock
The overall survival rate of patients with T-cell acute lymphoblastic leukemia (T-ALL) is now 90%, although patients with relapsed T-ALL face poor prognosis. The ubiquitin-proteasome system maintains normal protein homeostasis, and aberrations in this pathway are associated with T-ALL. Here we demonstrate the and activity of ixazomib, a second-generation orally available, reversible, and selective
-
EV-mediated intercellular communication in AML: Transport of genetic materials in the bone marrow microenvironment Exp. Hematol. (IF 2.6) Pub Date : 2024-02-02 Qi Zhou, Zijian Li, Yaming Xi
-
Minor introns impact on hematopoietic malignancies Exp. Hematol. (IF 2.6) Pub Date : 2024-02-02 Koutarou Nishimura, Wataru Saika, Daichi Inoue
-
Chromothripsis in hematologic malignancies Exp. Hematol. (IF 2.6) Pub Date : 2024-02-02 Francisco Alejandro Lagunas-Rangel
Chromotrypsis, a phenomenon resulting from catastrophic mitotic errors and genomic instability, is defined by the occurrence of multiple DNA double-strand breaks in one or more chromosomes, subsequently subject to error-prone repair mechanisms. This unique process results in extensive rearrangements in the affected chromosomes, leading to loss of tumor suppressor function, the creation of fusion genes
-
Publisher’s Note: Introducing article numbering to Experimental Hematology Exp. Hematol. (IF 2.6) Pub Date : 2024-01-25
-
-
Cell fate decision in erythropoiesis: Insights from multiomics studies Exp. Hematol. (IF 2.6) Pub Date : 2024-01-21 Steven Tur, Carmen G. Palii, Marjorie Brand
-
Computing Sickle Erythrocyte Health Index on quantitative phase imaging and machine learning Exp. Hematol. (IF 2.6) Pub Date : 2024-01-19 Yaw Ofosu Nyansa Ansong-Ansongton, Timothy D. Adamson
Sickle cell disease (SCD) is a genetic disorder characterized by abnormal hemoglobin and deformation of red blood cells (RBCs), leading to complications and reduced life expectancy. This study developed an in vitro assessment, the Sickle Erythrocyte Health Index, using quantitative phase imaging (QPI) and machine learning to model the health of RBCs in people with SCD. The health index combines assessment
-
Metabolic regulation of erythrocyte development and disorders Exp. Hematol. (IF 2.6) Pub Date : 2024-01-17 Junhua Lyu, Min Ni, Mitchell J. Weiss, Jian Xu
The formation of new red blood cells (RBC) (erythropoiesis) has served as a paradigm for understanding cellular differentiation and developmental control of gene expression. The metabolic regulation of this complex, coordinated process remains poorly understood. Each step of erythropoiesis, including lineage specification of hematopoietic stem cells, proliferation, differentiation, and terminal maturation
-
G-CSF–induced hematopoietic stem cell mobilization from the embryonic hematopoietic niche does not require neutrophils and macrophages Exp. Hematol. (IF 2.6) Pub Date : 2023-12-29 Ji Wook Kim, Evan A. Fedorov, Leonard I. Zon
Hematopoietic stem cell transplantation requires the collection of hematopoietic cells from patients or stem cell donors. Granulocyte colony-stimulating factor (G-CSF) is widely used in the clinic to mobilize hematopoietic stem and progenitor cells (HSPCs) from the adult bone marrow niche into circulation, allowing a collection of HSPCs from the blood. The mechanism by which G-CSF acts to mobilize
-
Nucleic acid-induced inflammation on hematopoietic stem cells Exp. Hematol. (IF 2.6) Pub Date : 2023-12-25 Giang To Vu, Valerie Awad, Maria Feliz Norberto, Teresa V. Bowman, Eirini Trompouki
-
Purging myeloma cell contaminants and simultaneous expansion of peripheral blood-mobilized stem cells Exp. Hematol. (IF 2.6) Pub Date : 2023-12-25 Kantaro Ishitsuka, Hidekazu Nishikii, Takaharu Kimura, Ayano Sugiyama-Finnis, Satoshi Yamazaki
Human hematopoietic stem cells (HSCs) are widely used as a cellular source for hematopoietic stem cell transplantation (HSCT) in the clinical treatment of hematological malignancies. After transplantation therapy, delays in hematopoietic recovery due to insufficient donor-derived HSCs can lead to increased risks of life-threatening infections and bleeding. Our previous studies developed an efficient
-
AKT2 inhibition accelerates the acquisition of phagocytic ability in induced pluripotent stem cell–derived neutrophils Exp. Hematol. (IF 2.6) Pub Date : 2023-12-14 Toshiya Hino, Fumio Nakahara, Masashi Miyauchi, Yusuke Ito, Yosuke Masamoto, Ken Morita, Yuki Kagoya, Hirotatsu Kojima, Mineo Kurokawa
Neutrophils are key components of the immune system that inhibit bacterial infections. Systemic bacterial infections can cause lethal conditions, especially in patients with neutropenia associated with chemotherapy or other systemic illnesses; hence, early detection of the symptoms and prompt management are crucial in such cases. Previously, we established expandable engineered neutrophil-primed progenitors
-
Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations Exp. Hematol. (IF 2.6) Pub Date : 2023-12-10 Mona A. Alqazzaz, Genna M. Luciani, Victoria Vu, Raquel A.C. Machado, Magdalena M. Szewczyk, Ella C. Adamson, Sehyun Cheon, Fengling Li, Cheryl H. Arrowsmith, Mark D. Minden, Dalia Barsyte-Lovejoy
Epigenetic regulators, such as the polycomb repressive complex 2 (PRC2), play a critical role in both normal development and carcinogenesis. Mutations and functional dysregulation of PRC2 complex components, such as EZH2, are implicated in various forms of cancer and associated with poor prognosis. This study investigated the epigenetic vulnerabilities of acute myeloid leukemia (AML) and myelodysp
-
Ex vivo hematopoietic stem cell expansion technologies: recent progress, applications, and open questions Exp. Hematol. (IF 2.6) Pub Date : 2023-12-09 Grace A. Meaker, Adam C. Wilkinson
Hematopoietic stem cells (HSCs) are a rare but potent cell type that support life-long hematopoiesis and stably regenerate the entire blood and immune system following transplantation. HSC transplantation represents a mainstay treatment for various diseases of the blood and immune systems. The ex vivo expansion and manipulation of HSCs therefore represents an important approach to ask biological questions
-
Characterization of Human Engraftment and Hemophagocytic Lymphohistiocytosis in NSG-SGM3 Neonate Mice Engrafted with Purified CD34+ Hematopoietic Stem Cells Exp. Hematol. (IF 2.6) Pub Date : 2023-12-04 Liam J O'Brien, Carina M Walpole, Ingrid M Leal-Rojas, Svetlana Shatunova, Andrew Moore, Ingrid G Winkler, Camille Guillerey, Kristen J Radford
Immunodeficient mice bearing human immune systems, or “humanized” chimeric mice, are widely used in basic research, along with the preclinical stages of drug development. Nonobese diabetic-severe combined immunodeficiency (NOD-SCID) IL2Rγ (NSG) mice expressing human stem cell factor, granulocyte-macrophage colony stimulating factor, and interleukin-3 (NSG-SGM3) support robust development of human myeloid
-
-
Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms Exp. Hematol. (IF 2.6) Pub Date : 2023-11-29 Almuth Maria Anni Merz, Uwe Platzbecker
Management of myelodysplastic neoplasms (MDS) requires a personalized approach, with a focus on improving quality of life and extending lifespan. The International Prognostic Scoring System-Revised and the molecular International Prognostic Scoring System are key tools for risk stratification and management of MDS. They provide a framework for predicting survival and the risk of transformation to acute
-
Understanding genetic heterogeneity in gene-edited hematopoietic stem cell products Exp. Hematol. (IF 2.6) Pub Date : 2023-11-29 Hans Jiro Becker, Satoshi Yamazaki
CRISPR/Cas gene editing has transformed genetic research and is poised to drive the next generation of gene therapies targeting hematopoietic stem cells (HSCs). However, the installation of the “desired” edit is most often only achieved in a minor subset of alleles. The array of cellular pathways triggered by gene editing tools produces a broad spectrum of “undesired” editing outcomes, including short
-
Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis Exp. Hematol. (IF 2.6) Pub Date : 2023-11-27 Shoko Sato, Midori Ishii, Kota Tachibana, Yoshiki Furukawa, Tokuko Toyota, Shintaro Kinoshita, Yoko Azusawa, Jun Ando, Miki Ando
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL), is characterized by Epstein-Barr virus infection and poor prognosis. We established a novel cell line, ENKL-J1, from bone marrow cells of an ENKL patient. We found that ENKL-J1 cells express the ganglioside GD2 (GD2) and that GD2-directed chimeric antigen receptor T cells exhibit cytotoxicity against ENKL-J1 cells, indicating that GD2
-
Transcriptional and functional consequences of Oncostatin M signaling on young Dnmt3a-mutant hematopoietic stem cells Exp. Hematol. (IF 2.6) Pub Date : 2023-11-23 Logan S. Schwartz, Kira A. Young, Timothy M. Stearns, Nathan Boyer, Kristina D. Mujica, Jennifer J. Trowbridge
-
Amyloid deposition through endocytosis in vascular endothelial cells Exp. Hematol. (IF 2.6) Pub Date : 2023-11-10 Seiji Nishikage, Akira Fujisawa, Hiromi Endoh, Hirotaka Sakamoto, Tomohide Suzuki, Maki Kanzawa, Shinichi Ishii, Mitsumasa Okano, Eriko Nitta, Kimikazu Yakushijin, Hidesaku Asakura, Kandai Nozu, Ryo Nitta, Yoshio Katayama, Kazuhiko Sakaguchi
No mechanistic lead is known for establishing AL amyloid deposits in organs. We here report an electron microscopic (EM) analysis in a case of intestinal AL amyloidosis before initiating treatment for amyloidosis. The dense deposits of amyloid fibrils are concentrated around the small blood vessels in the submucosal area of intestinal tissue. Surprisingly, we observed endothelial cells (ECs) of blood
-
Inhibitory effects of SARS-CoV-2 spike protein and BNT162b2 vaccine on erythropoietin-induced globin gene expression in erythroid precursor cells from patients with β-thalassemia Exp. Hematol. (IF 2.6) Pub Date : 2023-11-07 Lucia Carmela Cosenza, Giovanni Marzaro, Matteo Zurlo, Jessica Gasparello, Cristina Zuccato, Alessia Finotti, Roberto Gambari
-
Germline MPL mutations may be a rare cause of “triple-negative” thrombocytosis Exp. Hematol. (IF 2.6) Pub Date : 2023-11-07 Oscar Borsani, Daniela Pietra, Ilaria Carola Casetti, Daniele Vanni, Giacomo Riccaboni, Silvia Catricalà, Bossi Grazia, Emanuela Boveri, Luca Arcaini, Elisa Rumi
Hereditary thrombocytosis (HT) is a rare inherited disorder with clinical features resembling those of sporadic essential thrombocythemia. This study included 933 patients with persistent isolated thrombocytosis for whom secondary reactive causes were excluded. Of 933 patients screened, 567 were -mutated, 255 -mutated, 41 -mutated, 2 double-mutated, and 68 were triple-negative. Two patients carried
-
Editorial: Metabolic control in hematopoietic homeostasis, Edited by Keisuke Ito Exp. Hematol. (IF 2.6) Pub Date : 2023-11-04 Dr Ito Keisuke
Abstract not available
-
Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy Exp. Hematol. (IF 2.6) Pub Date : 2023-10-30 David M. Foureau, Fei Guo, Nury M. Steuerwald, Lawrence J. Druhan, Belinda R. Avalos, Edward Copelan, Danyu Sun, Bei Hu, Tamara Moyo, Ryan Jacobs, Steven Park, Nilanjan Ghosh
-
-
Metabolic regulation in erythroid differentiation by systemic ketogenesis in fasted mice Exp. Hematol. (IF 2.6) Pub Date : 2023-10-26 Wenjuan Ma, Yuichiro Arima, Terumasa Umemoto, Tomomasa Yokomizo, Yuqing Xu, Kenichi Miharada, Yosuke Tanaka, Toshio Suda
Erythroid terminal differentiation and maturation depend on an enormous energy supply. During periods of fasting, ketone bodies from the liver are transported into circulation and utilized as crucial fuel for peripheral tissues. However, the effects of fasting or ketogenesis on erythroid behavior remain unknown. Here, we generated a mouse model with insufficient ketogenesis by conditionally knocking
-
MiR-223-3p promotes genomic stability of hematopoietic progenitors after radiation Exp. Hematol. (IF 2.6) Pub Date : 2023-10-22 Shi Chen, Gayathri Srinivasan, Aruna Jaiswal, Elizabeth A. Williamson, Lingxiao Li, Dominic Arris, Daohong Zhou, Mingjiang Xu, Robert Hromas
When hematopoietic cells are overwhelmed with ionizing radiation (IR) DNA damage, the alternative non-homologous end-joining (aNHEJ) repair pathway is activated to repair stressed replication forks. While aNHEJ can rescue cells overwhelmed with DNA damage, it can also mediate chromosomal deletions and fusions, which can cause mis-segregation in mitosis and resultant aneuploidy. We previously reported
-
The multifaceted role of mitochondria in HSC fate decisions: energy and beyond Exp. Hematol. (IF 2.6) Pub Date : 2023-10-11 Marie-Dominique Filippi
Hematopoietic stem cells (HSCs) have the properties to self-renew and/or differentiate into all-mature blood cell lineages. The fate decisions to generate progeny that retain stemness properties or that commit to differentiation is a fundamental process to maintain tissue homeostasis and must be tightly regulated to prevent HSC overgrowth or exhaustion. HSC fate decisions are inherently coupled to
-
How nutrition regulates hematopoietic stem cell features Exp. Hematol. (IF 2.6) Pub Date : 2023-10-08 Katharina Schönberger, Nina Cabezas-Wallscheid
Our dietary choices significantly impact all the cells in our body. Increasing evidence suggests that diet-derived metabolites influence hematopoietic stem cell (HSC) metabolism and function, thereby actively modulating blood homeostasis. This is of particular relevance because regulating the metabolic activity of HSCs is crucial for maintaining stem cell fitness and mitigating the risk of hematologic
-
MiR-455-3p mediates PPARα through UBN2 to promote apoptosis and autophagy in acute myeloid leukemia cells Exp. Hematol. (IF 2.6) Pub Date : 2023-10-05 Yu Xie, Lin Tan, Kun Wu, Deyun Li, Chengping Li
Acute myeloid leukemia (AML) is one of the deadliest hematologic malignancies, and its targeted therapy has developed slowly. The molecular mechanism of the pathophysiology of the disease remains to be clarified. The aim of our study was to probe the specific regulatory mechanism of miR-455-3p in AML. This study measured the levels of miR-455-3p and ubinuclein-2 (UBN2) in AML cell lines, evaluated
-
Metabolic regulation of aged hematopoietic stem cells: key players and mechanisms Exp. Hematol. (IF 2.6) Pub Date : 2023-09-29 Nazanin Karimnia, James Harris, Shen Y. Heazlewood, Benjamin Cao, Susan K. Nilsson
Abstract not available
-
Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes Exp. Hematol. (IF 2.6) Pub Date : 2023-09-22 Chunling Fu, Xueting Hu, Shujin Wang, Xiangru Yu, Qigang Zhang, Liwei Zhang, Kunming Qi, Zhenyu Li, Kailin Xu
Most thrombopoietin receptor (MPL) mutations result in abnormal megakaryocyte expansion in the spleen or bone marrow (BM), leading to progressive fibrosis. It has been reported that p21 (Rac Family Small GTPase 1 [RAC1])-activated kinase 1 (PAK1) participates in the proliferation and differentiation of megakaryoblasts. PAK1 phosphorylation increased in patients with myeloproliferative neoplasms (MPNs)
-
Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions Exp. Hematol. (IF 2.6) Pub Date : 2023-09-22 Luca Guarnera, Enrico Santinelli, Elisa Galossi, Antonio Cristiano, Emiliano Fabiani, Giulia Falconi, Maria Teresa Voso
Acute myeloid leukemia (AML) is a disease with a dismal prognosis, mainly affecting the elderly. In recent years, new drugs have improved life expectancy and quality of life, and a better understanding of the genetic-molecular nature of the disease has shed light on previously unknown aspects of leukemogenesis.
-
Genetic mutation signature for relapse prediction in normal karyotype acute myeloid leukemia Exp. Hematol. (IF 2.6) Pub Date : 2023-09-20 Lijie Han, Jiaying Wu, Xiaodong Lyu, Jifeng Yu, Xiaolin Han, Hongmian Zhao, Zhilei Bian, Wei Li, Wenjuan Fan, Chen He, Weimin Wang, Mengmeng Zhang, Yafei Li, Chao Liu, Hui Sun, Haixia Cao, Li'na Sang, Jun Zhang, Zhongxing Jiang, Jie Peng
Risk stratification for normal karyotype acute myeloid leukemia (NK-AML) remains unsatisfactory, which is reflected by the high incidence of leukemia relapse. This study aimed to evaluate the role of gene mutations and clinical characterization in predicting the relapse of patients with NK-AML. A prognostic system for NK-AML was constructed. A panel of gene mutations was explored using next-generation
-
-
Physiological and regenerative functions of sterile-α motif protein-14 in hematopoiesis Exp. Hematol. (IF 2.6) Pub Date : 2023-09-16 Meg A. Schaefer, Pooja Roy, Srinivas Chava, Ainsley Meyerson, Andrew L. Duncan, Linda Chee, Kyle J. Hewitt
Sterile α-motif domain-14 (Samd14) protein expression increases the regenerative capacity of the erythroid system. Samd14 is transcriptionally upregulated and promotes cell signaling via the receptor tyrosine kinase Kit in a critical window of acute erythroid regeneration. We generated a hematopoietic-specific conditional Samd14 knockout mouse model (Samd14-CKO) to study the role of Samd14 in hematopoiesis
-
Corrigendum to ‘CCL8 deficiency in the host abrogates early mortality of acute graft-versus-host disease in mice with dysregulated IL-6 expression’ [Experimental Hematology 2022; 106: 47-57] Exp. Hematol. (IF 2.6) Pub Date : 2023-09-14 Keita Igarashi, Norio Takei, Tsukasa Hori, Masaki Yamamoto, Hitoshi Sohma, Nobuhiro Suzuki, Hiroyuki Tsutsumi, Yukihiko Kawasaki, Yasuo Kokai
Abstract not available
-
Chronic inflammation promotes cancer progression as a second hit Exp. Hematol. (IF 2.6) Pub Date : 2023-09-13 Monika Burocziova, Srdjan Grusanovic, Karolina Vanickova, Sladjana Kosanovic, Meritxell Alberich-Jorda
-
Effect of transplanted cells with CD184 and CD26 expressions and reconstitution of CD3+ lymphocyte population on long-term survival after autologous hematopoietic stem cell transplantation for multiple myeloma Exp. Hematol. (IF 2.6) Pub Date : 2023-09-04 Anna Kopinska, Małgorzata Krawczyk-Kulis, Agata Wieczorkiewicz-Kabut, Anna Koclega, Krystyna Jagoda, Joanna Dziaczkowska-Suszek, Grzegorz Helbig
Autologous hematopoietic stem cell transplantation (auto-SCT) is the recommended treatment for responding patients with multiple myeloma (MM). However, we do not know the risk factors influencing long-term survival without progression after auto-SCT. Therefore, this prospective study aimed to investigate the influence of transplanted cells with cluster of differentiation (CD)184+ expression, CD26+
-
Functional and molecular profiling of hematopoietic stem cells during regeneration Exp. Hematol. (IF 2.6) Pub Date : 2023-09-04 Anna Rydström, Tan H.M. Grahn, Abhishek Niroula, Els Mansell, Mark van der Garde, Maroulio Pertesi, Agatheeswaran Subramaniam, Shamit Soneji, Roman Zubarev, Tariq Enver, Björn Nilsson, Kenichi Miharada, Jonas Larsson, Stefan Karlsson
-
The role of extracellular vesicles on the occurrence of clinical complications in β-thalassemia Exp. Hematol. (IF 2.6) Pub Date : 2023-08-29 Mehrnaz Abdolalian, Mahin Nikogouftar Zarif, Mohammadreza Javan
-
Chronic inflammation can transform the fate of normal and mutant hematopoietic stem cells Exp. Hematol. (IF 2.6) Pub Date : 2023-08-28 Jingjing Li, Camille Malouf, Linde A. Miles, Mara B. Willis, Eric M. Pietras, Katherine Y. King
Chronic inflammation, although subtle, puts the body in a constant state of alertness and is associated with many diseases, including cancer and cardiovascular diseases. It leads hematopoietic cells to produce and release proinflammatory cytokines, which trigger specific signaling pathways in hematopoietic stem cells (HSCs) that cause changes in proliferation, differentiation, and migration. This response
-
Engineered hematopoietic and immune cells derived from human pluripotent stem cells Exp. Hematol. (IF 2.6) Pub Date : 2023-08-22 Yun Chang, Sydney N. Hummel, Juhyung Jung, Gyuhyung Jin, Qing Deng, Xiaoping Bao
For the past decade, significant advances have been achieved in human hematopoietic stem cell (HSC) transplantation for treating various blood diseases and cancers. However, challenges remain with the quality control, amount, and cost of HSCs and HSC-derived immune cells. The advent of human pluripotent stem cells (hPSCs) may transform HSC transplantation and cancer immunotherapy by providing a cost-effective
-
Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice Exp. Hematol. (IF 2.6) Pub Date : 2023-08-21 Daniel A.C. Fisher, Angelo B.A. Laranjeira, Tim Kong, Steven C. Snyder, Kevin Shim, Mary C. Fulbright, Stephen T. Oh
-
A Bloody Feast—Nutritional Regulation of Hematopoiesis Exp. Hematol. (IF 2.6) Pub Date : 2023-08-13 Noga Ussishkin, Daphna Nachmani
Hematopoietic stem cells provide us with a lifelong supply of blood cells. Hence, their proper function is absolutely essential for life, and their dysfunction can lead to infectious and malignant diseases. These cells have specific metabolic requirements to enable their lifelong function and blood-producing capacity. With the words of the Roman poet Juvenal “a healthy mind in a healthy body” in mind
-
Epidemiology of Chronic Lymphocytic Leukemia in Sardinia, Italy (1974–2003) Exp. Hematol. (IF 2.6) Pub Date : 2023-08-09 Giorgio Broccia, Jonathan Carter, Cansu Ozsin-Ozler, Sara De Matteis, Pierluigi Cocco
Several reports have described a worldwide increasing incidence of chronic lymphocytic leukemia (CLL) dating back seven to eight decades. Although genetic susceptibility would be an implausible explanation, the determinants of this upward trend and its spatial coordinates are poorly understood. We explored CLL incidence in Sardinia, Italy, using a validated database including the 1700 CLL cases diagnosed
-
Myeloid Hif2α is not essential to maintain systemic iron homeostasis Exp. Hematol. (IF 2.6) Pub Date : 2023-08-08 Chesta Jain, Sanjana Parimi, Wesley Huang, Sean Hannifin, Rashi Singhal, Nupur K. Das, Kyoung Eun Lee, Yatrik M. Shah
Dietary consumption serves as the primary source of iron uptake, and erythropoiesis acts as a major regulator of systemic iron demand. In addition to intestinal iron absorption, macrophages play a crucial role in recycling iron from senescent red blood cells. The kidneys are responsible for the production of erythropoietin (Epo), which stimulates erythropoiesis, whereas the liver plays a central role
-
Corrigendum to ’ 5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9’ [Volume 114, October 2022, Pages 43-53.e2] Exp. Hematol. (IF 2.6) Pub Date : 2023-08-05 Congmeng Lin, Yongxin Xie, Wenwen Huang, Dayi Lin, Luhui Lin
Abstract not available
-
Expanding hematopoietic stem cell ex vivo: recent advances and technical considerations Exp. Hematol. (IF 2.6) Pub Date : 2023-08-03 Juan A. Rubio-Lara, Kyomi J. Igarashi, Shubhankar Sood, Alban Johansson, Pia Sommerkamp, Masayuki Yamashita, Dawn S. Lin
Hematopoietic stem cells (HSCs) are the most primitive cell type in the hematopoietic hierarchy, which are responsible for sustaining the lifelong production of mature blood and immune cells. Due to their superior long-term regenerative capacity, HSC therapies such as stem cell transplantation have been used in a broad range of hematologic disorders. However, the rarity of this population in vivo considerably
-
-
Good prognosis of adult hemophagocytic lymphohistiocytosis associated with the germline HAVCR2 mutation Exp. Hematol. (IF 2.6) Pub Date : 2023-07-19 Pitchayut Boonyabaramee, Chantana Polprasert, Sirorat Kobbuaklee, Rung Settapiboon, Saranya Pongudom, Saruta Faknuam, Sunisa Kongkiatkamon, Kitsada Wudhikarn, Ponlapat Rojnuckarin
Hemophagocytic lymphohistiocytosis (HLH) in adults may be idiopathic or secondary to various conditions. Recent studies identified germline hepatitis A virus-cellular receptor 2 (HAVCR2) mutations in subcutaneous panniculitis-like T-cell lymphoma (SPTCL) with HLH. The roles of this mutation in HLH, especially in idiopathic group, have never been explored. Of the 65 HLH cases, we detected germline HAVCR2Y82C
-
Effects of ruxolitinib on murine regulatory T cells are immune-context dependent Exp. Hematol. (IF 2.6) Pub Date : 2023-07-17 Nidhi Aggarwal, Ash Lee Manley, Jichun Chen, Emma M. Groarke, Xingmin Feng, Neal S. Young
Aplastic anemia is a bone marrow failure (BMF) disorder characterized by pancytopenia and hypocellular marrow from an immune-mediated etiology. Regulatory T cells (Tregs) prevent autoimmunity by suppressing autoreactive T cells. We recently demonstrated the efficacy of ruxolitinib (RUX), a JAK 1/2 inhibitor, in attenuating murine BMF. Herein, we investigated the changes of Tregs in the context of RUX
-
New insight into the causes, consequences, and correction of hematopoietic stem cell aging Exp. Hematol. (IF 2.6) Pub Date : 2023-07-09 Els Mansell, Dawn S. Lin, Stephen J. Loughran, Michael D. Milsom, Jennifer J. Trowbridge
Aging of hematopoietic stem cells (HSCs) is characterized by lineage bias, increased clonal expansion, and functional decrease. At the molecular level, aged HSCs typically display metabolic dysregulation, upregulation of inflammatory pathways, and downregulation of DNA repair pathways. Cellular aging of HSCs, driven by cell-intrinsic and cell-extrinsic factors, causes a predisposition to anemia, adaptive